Morgan Stanley Maintains Overweight on Eli Lilly, Raises Price Target to $673
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst David Phung has maintained an Overweight rating on Eli Lilly (NYSE:LLY) and raised the price target from $640 to $673.
October 11, 2023 | 1:36 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Morgan Stanley has maintained an Overweight rating on Eli Lilly and raised the price target from $640 to $673, which could positively impact the stock's price.
The Overweight rating maintained by Morgan Stanley indicates a positive outlook for Eli Lilly. The increase in the price target from $640 to $673 suggests that the analyst believes the stock has potential for further growth. This could lead to increased investor confidence and a potential rise in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100